score matching, which represents the probability of each patient to be assigned to a particular treatment, given a set of known covariates ( 5 ) . On the contrary, Feng et al. individually matched patients in the two groups without performing propensity score analysis. Th is approach is not suffi cient to completely prevent the risk of selection bias. Furthermore, the lack of blinding of outcome evaluators (inevitable in a retrospective study) may have led to a detection bias, particularly in terms of recurrence and safety profi le assessment.
Th e aforementioned concepts stress the need for further robust results provided by prospective trials to defi ne the role of sorafenib as an adjuvant treatment in HCC patients.
To the Editor:
We read with great interest the article by Feng et al. "Combination Th erapy with Sorafenib and Radiofrequency Ablation for BCLC Stage 0-B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study" ( 1 ), published in the American Journal of Gastroenterology , where the combination of sorafenib and radiofrequency ablation (RFA) was associated with better survival outcomes in patients with Barcelona Clinic Liver Cancer (BCLC) 0-B1 hepatocellular carcinoma (HCC). Th e study is a well-conducted retrospective multicenter comparison between 64 patients who received sorafenib plus RFA and 64 patients treated with RFA alone. Th e results of this paper are in keeping with other retrospective reports and con fi rm the role of sorafenib aft er RFA, mainly due to the suppression of neo-angiogenesis triggered by post-treatment necrosis ( 2, 3 ) .
However, despite the promising results of these retrospective reports and the theoretical advantages of sorafenib in an adjuvant setting, a broad multicenter randomized-controlled trial (Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)), enrolling 1114 HCC patients aft er resection or RFA, failed to fi nd a signifi cant improvement in recurrence-free survival (primary endpoint) and overall survival ( 4 ). Th is disappointing result was partly related to the high discontinuation rate of therapy, because of severe adverse events (24% in the sorafenib group) or consent withdrawal (17%). On the other hand, the very low rate of drug interruption reported by Feng et al. (6%) is of interest.
Th ese discrepancies further point out the limits of retrospective studies whose results should always be considered with caution.
In fact, all the retrospective reports are aff ected by a number of biases. For instance, in the study by Feng et al. , it is not clear how patients were selected (BCLC 0-B1 patients are not routinely off ered sorafenib, neither alone nor in combination with other treatments) and how the matching was performed. In retrospective studies, the best statistical tool to overcome selection bias is the propensity
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Th e authors declare no confl ict of interest. characteristics of our study (Table 2) , we could easily discern that recurrent tumors or previously treated tumors, including surgical resection, liver transplantation, transcatheter arterial chemoembolization (TACE) or RFA, comprised the majority of our study population (i.e., 48 (75%) in the RFA+sorafenib group and 40 (62.5%) in the RFA group), which was obviously diff erent from the eligible population enrolled in the STORM trial (i.e., all newly diagnosed HCC without any anti-cancer treatment). Also, there was a higher rate of recurrent tumors in the sorafenib+RFA group than in the RFA alone group in our study ( P =0.046).
Furthermore, from the results, we can see that the median time to recurrence (TTR) in our study was 15.2 months (95% confi dence interval (CI), 9.1-21.3) in the sorafenib-RFA group and 9.6 months (95% CI, 6.3-12.9) in the RFA group. Accordingly, the TTR in the STORM trial was 38.6 months (95% CI, 30.4-not available) in the sorafenib group and 35.8 months (95% CI, 30.3-41.4) in the placebo group.
Because local therapies maybe aff ectrelated gene expression and the tumor microenvironment of these tumor cells, we postulate that the biological behavior of tumor cells in the patients with recurrence in our study might present with more furious and invasive characteristics than in the intermediate and a high risk for recurrence patients of the STORM study ( 4 ) . Th e tumor cells in recurred HCC may grow faster than in non-recurred HCC or may not easily process apoptosis. It is known that sorafenib blocks both tumor cell proliferation and angiogenesis in HCC cells; we therefore presume that sorafenib restrains growth of the tumor cells in recurred HCC by blocking the targeted multiple pathways, especially angiogenesis sorafenib may have an important role in HCC patients who have recurred.
On the other hand, this hypothesis may only get limited clues from on-hand reported clinical studies. For example, sorafenib may represent a therapeutic option for recurrent HCC aft er liver transplantation (LT) with manageable side eff ects ( 5 ) . Another pilot study to review the use of sorafenib in recurrent HCC LTx in the Model End Stage Liver Disease era ethanol injection (PEI)) as an entire eligible population and assumed that all the patients had homogeneity for risk of recurrence, and then they used randomization for group assignment.
Until recently, most studies from a PubMed search related to surgical resection and local ablation in treating hepatocellular carcinoma (HCC) showed that, although RFA of HCC may achieve good local control, surgical resection may provide better survival and lower recurrence rates than RFA for patients with HCC according to the Milan criteria ( 2 ) . In addition, several randomized controlled trials (RCTs) have demonstrated an inferior effi cacy of PEI compared with RFA ( 3 ). Hence, it could be postulated that the eligible patients in the STORM study were more heterogeneous for the risk of recurrence, not only brought by the initial tumor characteristics (i.e., intermediate or high recurrence risk), but also by diff erent treatment methods (i.e., hepatic resection or RFA or PEI). Although stratifi cation on resection vs. ablation was presented, it might be better to carry out an independent trial to study the combination of RFA+sorafenib on early HCC as a good quality control study.
On the basis of these diff erences, we propose that an appropriate comparison of results should be presented between our study and a subgroup population of the STORM study only including patients with HCC treated by RFA--i.e., not including those that underwent hepatectomy and PEI. Unfortunately, from the American Society of Clinical Oncology presentation, we could not get enough information for further analysis.
2. Diff erent tumor situations of the enrolled patients between the two studies.
Th e inclusion criteria of the STORM study was defi ned as single tumor 2-3 cm in the group with intermediate risk of recurrence, single tumor ≥3-5 cm, or 2-3 tumors each ≤3 cm in the group with a high risk of recurrence, which means the patients who had been enrolled in STORM trail were all at intermediate and high risk for recurrence. Th erefore, these patients had no recurrence before entering the STORM study. In addition, no prior local therapy was received by the HCC patients of the STORM study, which was diff erent from this study. In the tumor baseline 
